Form 4 for PFE Pfizer
Accepted 2025-03-03 00:00:00 ET · period of report 2025-02-27 · accession 0001225208-25-002708 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-03 | 2025-02-27 | PFE | SUSMAN SALLY | EVP | M - OptEx | $31.31 | +85.2K | 250.9K | +51% | +$2.67M |
| DM | 2025-03-03 | 2025-02-27 | PFE | SUSMAN SALLY | EVP | F - Tax | $26.06 | -82.0K | 168.9K | -33% | -$2.14M |
| D | 2025-03-03 | 2025-02-27 | PFE | SUSMAN SALLY | EVP | M - OptEx | $0.00 | -85.2K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-27 | M | A | 85,182 | $31.31 | 250,866 | D | — | — | (F1) The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). |
| 2 | Common | Common Stock | 2025-02-27 | F | D | 2,178 | $26.10 | 248,688 | D | — | — | (F2) The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. |
| 3 | Common | Common Stock | 2025-02-27 | F | D | 79,779 | $26.06 | 168,909 | D | — | — | (F3) The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). (F4) Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. |
| 4 | Derivative | Stock Appreciation Rights | 2025-02-27 | M | D | 85,182 | $0.00 | 0 | D | $31.31 · 2025-02-27 to 2025-02-27 | 85,182 Common Stock |